Introduction
NF-kB is a family of dimeric transcription factors, normally sequestered in the cytoplasm of non-B cells by specific inhibitory proteins termed IkBs, of which IkB-a is the best characterized (Baldwin, 1996) . NF-kB factors regulate expression of a variety of genes involved in apoptosis, cell cycle, transformation, immune response, and cell adhesion (Barkett and Gilmore, 1999) . For example, we demonstrated that inhibition of constitutive NF-kB activity in B cells or hepatocytes upon treatment with transforming growth factor-b1 (TGF-b1) resulted in apoptosis (Arsura et al., 1996 (Arsura et al., , 1997 . Furthermore, RelA, IKK-2 and IKK-g knockout mice died prematurely in utero because of TNF-a-induced liver apoptosis (Beg et al., 1995; Li et al., 1999b; Rosenfeld et al., 2000; Rudolph et al., 2000) , and NF-kB rescued cells from TNF-a-induced apoptosis through disruption of JNK signaling via induction of NF-kB downstream targets (De Smaele et al., 2001; Tang et al., 2001) . Many agents can activate NF-kB DNA binding, including proinflammatory cytokines, such as TNF-a, and growth factors. Upon TNF-a stimulation, IkB-a is phosphorylated at Ser32 and Ser36 by the IkB kinase (IKK) complex, which is formed by the IKK-1 and IKK-2 catalytic subunits, and by a scaffold subunit termed IKK-g/NEMO (Mercurio and Manning, 1999) . As a consequence of phosphorylation, IkB-a protein is rapidly ubiquitinated on lysine residues 21 and 22, and degraded through the proteasome pathway , allowing for migration of NF-kB to the nucleus. Alternatively, some agents and oncogenes activate NF-kB via a casein kinase CK2/calpain pathway (Pianetti et al., 2001) . Unfortunately, much less is known about the mechanisms that leads to inhibition of constitutive activation of NF-kB, which occurs in B cells or cancer cells, for example, hepatocellular carcinomas.
TGF-b1 belongs to a large superfamily of structurally related cytokines, which regulates a variety of physiological processes (Massague, 1996) . TGF-b1 treatment induced death of primary cultures of rat hepatocytes and murine hepatocyte cell lines (Oberhammer et al., 1992; Arsura et al., 1997) . Furthermore, hepatic expression of mature TGF-b1 in transgenic mice resulted in multiple tissue lesions, including hepatic fibrosis and apoptotic death of hepatocytes (Sanderson et al., 1995) . TGF-b1 can signal through intracellular mediators known as Smads, which are localized in the cytoplasm (Attisano and Tuen Lee-Hoeflich, 2001 ). Following TGF-b1 receptor-mediated phosphorylation, Smad2 and 3 associate as heteromeric complexes with the common signaling mediator Smad4 and translocate into the nucleus to regulate gene expression. The inhibitory Smad7 competes for binding with Smad2 and 3 to the activated TGF-b1 receptor and promotes ubiquitinmediated receptor degradation, thereby suppressing TGF-b1 signaling (Attisano and Tuen Lee-Hoeflich, 2001 ). Additionally, TGF-b1 can signal through the TGF-b1-activated kinase 1 (TAK1) which belongs to the mitogen-activated protein kinase kinase kinase (MAPKKK) family (Yamaguchi et al., 1995) , which can also be regulated by other receptors involved in immune response including the TNFR (Sakurai et al., 1999) , IL-1R (Takaesu et al., 2000) , and toll-like receptor(s) . Following proinflammatory cytokine stimulation TAK1 induced MAP kinase (MKK) 4, MKK3, and MKK6 activities, which in turn activated the c-Jun N-terminal kinase (JNK) and the p38 MAPK cascades (Moriguchi et al., 1996; Shirakabe et al., 1997; Yao et al., 1999) . In particular, JNKmediated activation of the AP-1 complex cooperated with Smads in the induction of TGF-b1-dependent transcription (Zhang et al., 1998; Engel et al., 1999) and apoptosis (Yamamura et al., 2000) . Furthermore, TAK1 directly phosphorylated the IKK complex in response to TNF-a, IL-1 or LPS treatment, promoting NF-kB activation (Sakurai et al., 1999; Irie et al., 2000; Takaesu et al., 2000) .
We identified NF-kB as an additional downstream target of TGF-b1 signaling (Arsura et al., 1996 (Arsura et al., , 1997 . TGF-b1 treatment of B-cell lymphomas, hepatocytes, breast cancer, and salivary gland cells downregulated NF-kB activity causing cell death or growth arrest (Arsura et al., 1996 (Arsura et al., , 1997 Azuma et al., 1999; Sovak et al., 1999) . Little was known about the mechanism underlying these effects of TGF-b1 on NF-kB. We and others showed that TGF-b1 induced transcription of the IkB-a-inhibitor gene (Arsura et al., 1996; Azuma et al., 1999) , which sequestered NF-kB in the cytoplasm (Arsura et al., 1997; Sovak et al., 1999) . Here, we report that TGF-b1 causes an initial transient induction of NF-kB activity, preceding the observed downregulation, which is mediated by early activation of the TAK1 and IKK complex. In addition, we show that NF-kB inhibits TGF-b1-induced apoptosis through suppression of JNK signaling rather than through upregulation of Smad7. Lastly, TGF-b1-or TGF-a/c-myc-induced hepatocellular carcinomas displayed constitutive NF-kB activity, which led to inhibition of the JNK and AP-1 complex activity. Thus, we propose that IKKs mediate a protective mechanism in response to TGF-b1 with implications in neoplastic progression of liver epithelial cells.
Materials and methods

Mice
TGF-b1 transgenic and wild-type (wt) mice were generated in B6CBA background as described previously (Sanderson et al., 1995) . Both HCCs and surrounding livers were obtained from 16 to 17-week-old TGF-b1 transgenic mice. The animal study protocols were conducted according to National Institutes of Health guidelines for animal care. Mice had free access to standard rodent chow and water.
Cell culture and treatment conditions
Normal murine hepatocyte (NMH) cells (Wu et al., 1994) and Hs578 T breast cancer cells were maintained as described previously (Arsura et al., 1997; Sovak et al., 1999) . Murine embryo (10)1 fibroblasts were grown in DMEM with 10% fetal bovine serum (Gibco/BRL), 100 mg/ml streptomycin. 223 ma2 cells were isolated from an HCC of a TGF-a/c-myc transgenic mouse and maintained in DMEM/Ham F12 high glucose w/o glutamine (Gibco/BRL), 1 mg/ml d-galactose, 30 mg/ml proline, 2 mm glutamine, 5 mm sodium pyruvate, 18 mm HEPES, 5 ng/ml insulin, 5 mg/ml transferrin, 5 ng/ml selenium, 100 mg/ml streptomycin and 10% fetal bovine serum (Gibco/BRL). Where indicated, cells were incubated either with 2 or 5 ng/ml TGF-b1 (Austral Biological, San Ramon, CA, USA) dissolved in 0.1% BSA or carrier BSA as control, or 20 ng/ml TNF-a (Sigma).
Transfection conditions
For transient transfection, NMH and (10)1 cells were transfected with a solution of DNA and Lipofectamine tm Reagent according to the manufacturer's instructions (Gibco/BRL). At 16 h after transfection, cells were treated with 5 ng/ml TGF-b1 or BSA carrier solution for 5 h. Cells were harvested after treatment according to the manufacturer's protocol in the Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA), and lysates analysed with a Labsystems Luminoskan 96-well plate luminometer (Thermolab System, Needham Heights, MA, USA). Firefly luciferase activity was normalized for renilla luciferase activity and results were expressed as a ratio (fold induction) of normalized luciferase activities in treated cells versus vehicle-treated cells. Alternatively, lysates were subjected to CAT chloramphenicol acetyltransferase assay as described previously (Lee et al., 1995) . Standard deviation was obtained using the Student's ttest.
Plasmids and adenoviruses
The URE-kB-thymidine kinase (TK)-CAT plasmid (E8-CAT) and its double mutated version (dmE8-CAT) have been previously described (Duyao et al., 1990) . The 0.4SK-luc construct (Le Bail et al., 1993) contains 380 bp of the upstream region of the human IkB-a gene driving a luciferase reporter gene. The phosphorylation-defective mutants IKK-1 SS/AA and IKK-2 SS/AA (Mercurio et al., 1997) , and the pMT2T-IkB-a and pMT2T-RelA (Brown et al., 1995) are as described. The dominant-negative (dm) IkB-a 3C/2N-IkBa, SS/AA, and RR/LL have been described elsewhere (Barroga et al., 1995; DiDonato et al., 1996) . The dn TAK1-K63W (Yamaguchi et al., 1995) was a kind gift of Dr Sakurai (Tanabe Seiaku Co., Osaka, Japan). The wtIkB-a-GST was a generous gift of J Hiscott (Institut Lady Davis de Recherches Medicales, Montreal, Quebec, Canada) (Lin et al., 1996) . The XIAP expression vector was a kind gift of Dr R Korneluk (Conte et al., 2001) . The rcDNA/Myc-DFosB (Yamamura et al., 2000) have been described previously. The SflI-XhoI fragment of the upstream regulatory sequence of the murine Smad7 promoter was cloned into the pGL-3 basic vector (Brodin et al., 2000) . The 4XTRE-luc construct contains four repeats of the TPAresponsive element (TRE) driving a luciferase reporter gene (Williams et al., 2001) . The adenoviral vectors expressing wtIKK-1, wtIKK2, or dn forms of IKK-1 (IKK-1 K>M) or IKK-2 (IKK-2 K>M), were constructed by blunt ligation of the respective IKK cDNA into the replication-deficient vector pAxCA. Virus stocks were amplified to high titer (Quantum Biotechnologies, Montreal, Canada). The concentration of viral particles (VP) was determined by OD260 measurement. Plaque assay and TCID50 assays to determine infectous virus units (IU) gave a VP : IU ratio of less than 100 : 1. Adenoviral preparations were retitered using human umbilical vein endothelial cells to determine the optimum MOI.
EMSA
Nuclear extracts were prepared from cells (Arsura et al., 2000) or from livers (Factor et al., 2001) , as described previously. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). The sequences of the URE-kB, Octamer-1 (Oct-1), and AP-1 oligonucleotides are as follows: URE-kB:
0 EMSA was performed, as described previously (Arsura et al., 2000) using approximately 2 ng of labeled oligonucleotide (20, 000 d.p.m.) and 5 mg nuclear extract and complexes resolved in 4.5% polyacrylamide gels.
RNA isolation and analysis
Total cellular RNA was isolated by the guanidinium method following the manufacturer's instructions (Qiagen, Valencia, CA, USA) and samples (10-20 mg) subjected to Northern blot analysis, as described previously (Lee et al., 1995) .
Immunoblot analysis and IKK kinase assay
For isolation of whole-cell extracts (WCEs), cells were resuspended in cold PD buffer [40 mm Tris (pH 8), 500 mm NaCl, 6 mm EDTA, 6 mm EGTA, 10 mm glycerophosphate, 10 mm NaF, 10 mm p-nitrophenyl phosphate (PNPP), 300 mm Na 3 V0 4 , 1 mm benzamidine, 2 mm PMSF, 1 mm DTT, 1 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mg/ml pepstatin, and 0.5% NP-40] and sheared through a syringe needle (25 G). Extracts were then cleared by centrifugation at 40 000 r.p.m. for 30 min. at 41C. The IKK and JNK kinase assay was performed essentially as described previously (Arsura et al., 2000) . Samples (20-40 mg) were subjected to electrophoresis on a 10% polyacrylamide (PAGE)-SDS gel, and immunoblotting performed as previously described (Arsura et al., 1996) . The antibody preparations for IkB-a (sc-371), IKK-1 (sc-7182), IKK-2 (sc-7607), and CK2 (sc-6479) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The antibody specific for the phosphorylated form of IkB-a was purchased from Sigma. The mouse anti-human JNK-1 monoclonal antibody was obtained from BD Pharmingen (San Diego, CA, USA).
Results
TGF-b1 treatment leads to transient induction of NF-kB and IkB-a promoter activity
To assess the initial NF-kB response to TGF-b1 treatment, we analyzed normal murine hepatocytes (NMH), which display constitutive NF-kB activity (Arsura et al., 1997) . The upstream NF-kB element (URE-kB) from the c-myc gene was used as probe (Duyao et al., 1990) . Following TGF-b1 treatment, NFkB binding activity initially increased at the 3 h time point and then started to decrease so that it was below control levels at 24 h (Figure 1a ), as we observed previously (Arsura et al., 1997) . Similar results were obtained using the Hs578 T breast cancer cell line (data not shown), and the murine embryo fibroblast cell line (10)1 (Figure 1b) , indicating that TGF-b1-mediated induction of NF-kB is not restricted to epithelial cells. To verify an early induction of functional NF-kB activity, transfection analysis was performed using wild-type and mutant NF-kB element driven reporter construct E8-CAT and dmE8-CAT (Duyao et al., 1990) . As shown in Figure 1c , TGF-b1 treatment of NMH cells for 2.5 h increased E8-CAT activity by approximately three-fold, while only modestly affecting the low basal CAT activity of the dmE8-CAT construct. Coexpression of the phosphorylation-defective IkB-a mutant IkB-a SS/AA or of the ubiquitination-defective IkB-a LL/RR blocked the activation of the E8-CAT construct mediated by TGF-b1 (Figure 1c) . Thus, TGF-b1 treatment leads to an early transient induction of functionally active NF-kB.
Since we observed a threefold to sixfold induction of IkB-a mRNA levels in response to TGF-b1 treatment of NMH cells (data not shown), we next sought to determine whether NF-kB activation mediated upregulation of IkB-a promoter activity. As shown in Figure 1d , TGF-b1 treatment for 2.5 h induced the activity of the human IkB-a promoter 0.4SK-luc construct an average of 2.7-fold, consistent with regulation at a transcriptional level seen previously in B cells (Arsura et al., 1996) . Coexpression of either IkBa SS/AA or IkB-a LL/RR mutant blocked activation of the IkB-a promoter ( Figure 1d ). Thus, the induction of NF-kB upon TGF-b1 treatment of NMH cells plays a major role in the activation of the IkB-a expression, which presumably promotes the subsequent decline in NF-kB levels.
IKK-1 and IKK-2 mediate TGF-b1-induced phosphorylation of IkB-a
Since we observed increased phosphorylation of IkB-a protein at serine residues at positions 32 and 36 in response to 30 min of TGF-b1 treatment of Hs578 T cells (data not shown), we sought to determine the effects of TGF-b1 on IKK complex activity. NMH cells were treated for 30 min with TGF-b1 or BSA carrier solution as control, extracts were prepared, and samples were subjected to kinase assays using wt IkB-a GST fusion protein as substrate. Low basal activity was observed with immunoprecipitated IKK-1 and IKK-2 from BSA-treated NMH cells (Figure 2a , top panel), consistent with the low constitutive NF-kB activity seen in these cells (Arsura et al., 1997; Sovak et al., 1999) . Treatment with TGF-b1 resulted in an approximate threefold increase in kinase activity in both the IKK-1 and IKK-2 immunoprecipitates. Thus, TGF-b1 appears to activate both IKK-1 and IKK-2.
To assess the ability of IKK-1 and IKK-2 to regulate NF-kB activation in response to TGF-b1 treatment, we turned to the (10)1 embryoblasts, and infection with adenoviral constructs, where we routinely achieved an infection efficiency of B95% as assessed by GFP staining and immunoblotting (data not shown). Cells were infected with adenoviral vectors expressing wt or dn forms of IKK-1 (IKK-1 K>M) or IKK-2 (IKK-2 K>M) (Mercurio et al., 1997) . After 24 h, cells were treated for 5 h with either TGF-b1 (Figure 2b ), or TNFa (Figure 2c ), as a control for an IKK-mediated pathway. As judged by EMSA, expression of either dn IKK-1 K>M or IKK-2 K>M blocked the induction of NF-kB as compared to uninfected cells (Figure 1b) or cells expressing wtIKK-1 or wtIKK-2 ( Figure 2b ). As expected, only IKK-2 K>M, but not IKK-1 K>M, affected NF-kB activation in response to TNF-a treatment (Figure 2c ), in good agreement with previous reports (Mercurio et al., 1997; Li et al., 1999a) . To verify the effects of the IKK dn mutants on activation of NFkB by TGF-b1 in NMH cells, transient transfection was performed with the wt NF-kB reporter construct E8-CAT in the absence or presence of the adenoviral vectors. The parental vectors pRC-bactin and pCMV2 were used as controls. A fourfold to sixfold increase in relative E8-CAT activity was observed in response to TGF-b1 treatment in the presence of the parental vectors ( Figure 2d ). In contrast, ectopic expression of dn IKK-1 or IKK-2 mutants completely ablated the induction of NF-kB transcriptional activity by TGF-b1. Thus, the activity of both IKK-1 and IKK-2 kinase subunits mediates induction of NF-kB DNA binding activity following TGF-b1 treatment. 
Figure 1 NF-kB is transiently activated in response to TGF-b1 treatment. Normal murine hepatocytes (NMH) (a) or murine embryo fibroblasts (10)1 (b) were treated for the indicated times with 5 ng/ml TGF-b1 (T) or BSA carrier solution (B), as control. To measure the levels of NF-kB binding activity, nuclear extracts (5 mg) were subjected to EMSA using the upstream NF-kB element from the cmyc gene (URE-kB) as a probe (Duyao et al., 1990) . Band 1 represents classical NF-kB (p65/p50), band 2 contains p50 homodimers. As control for equal loading, EMSA was also performed with an Oct-1 probe. (c) NF-kB transcriptional activity. NMH cells were transiently transfected by lipofection, in triplicate with 5 mg E8-CAT or dmE8-CAT reporter construct plus 500 ng pON407 b-Gal reporter vector. The E8-CAT vector has two copies of URE-kB element upstream of the TK promoter driving the CAT reporter. Alternatively, the double mutant vector (dmE8-CAT) has two copies of a mutant version of the URE element with two G to C conversions, which is unresponsive to NF-kB transactivation. At 24 h after transfection, NMH cells were treated for 2.5 h with 2 ng/ml TGF-b1 and extracts were prepared and normalized for b-Gal activity as described previously (Lee et al., 1995) . The values for E8-CAT activity are represented as fold induction over dmE8-CAT activity, which was set at 1.0. Means and standard deviations are representative of two independent experiments carried out in triplicate. (d) The increase in IkB-a promoter activity following TGF-b1 treatment of NMH cells is mediated by NF-kB. NMH cells in P60 cultures were transfected with lipofectamine with 2 mg human IkB-a promoter 0.4SK-luc construct in the absence or presence of 1 mg of either pRC-b-actin parental vector or of dominant negative IkB-a SS/AA or LL/RR mutants. Cultures were treated with 2 ng/ml TGF-b1 for 2.5 h and luciferase activity was measured and expressed as fold induction relative to that of BSA-treated control cells. Means and standard deviations are representative of three independent experiments carried out in triplicate. Bars represent standard deviations Role of NF-jB in TGF-b1-induced apoptosis M Arsura et al TAK1 mediates IKK-1 activation and NF-kB translocation in response to TGF-b1 treatment While the TGF-b activated kinase 1 (TAK1) had been implicated in IkB-a phosphorylation through the IKK complex by TNF-a, LPS and IL-1 signaling (Sakurai et al., 1998 (Sakurai et al., , 1999 Irie et al., 2000; Takaesu et al., 2000 Takaesu et al., , 2001 Holtmann et al., 2001) , TAK1 or NF-kB activation was not observed in TGF-b1-treated HeLa cells (Sakurai et al., 1999) . Given the observed activation of NF-kB in NMH cells, we next examined the role of TAK1 activity in IKK activation upon TGF-b1 treatment. Flag-tagged TAK1 kinase inactive mutant FLAG-TAK1K63W or empty pCMV2 vector DNA was transiently transfected into NMH cells. Ectopic expression of the TAK1K63W mutant was confirmed by immunoblotting using an anti-Flag antibody (Figure 3a , bottom panel). Following 30 min of TGF-b1 or BSA treatment, WCEs were isolated and IKK-1 immunoprecipitants were subjected to kinase assays. Both basal and TGF-b1-induced phosphorylation of IkB-a-GST were greatly diminished in the TAK1K63W compared to pCMV2 transfected cells (Figure 3a, top panel) . The presence of approximately equal amounts of IKK-1 in the immunoprecipitates was verified by immunoblotting ( Figure 3a , middle panel). Furthermore, ectopic expression of the TAK1K63W dn construct ablated the induction of NF-kB transcriptional activity in response to TGF-b1 (Figure 3b ). These findings indicate a role for TAK1 in mediating TGF-b1 activation of the IKK-1 subunit and NF-kB translocation in NMH cells, thereby implying that TGF-b1 activated TAK1.
TGF-b1 induces Smad7 gene expression independent of NF-kB activation
Since Smad7 can be induced in response to TGF-b1 (Nakao et al., 1997; Afrakhte et al., 1998) and protected from TGF-b1-induced apoptosis (Yamamura et al., 2000) , we next examined the role of Smad7 in protection of NMH cells from TGF-b1-induced death. For this purpose, cells were transfected with a human Smad7 expression vector or with constructs directing expression of the 2N/3C IkB-a mutant inhibitory protein or the RelA subunit to modulate NF-kB levels. Approximately, 30% of pCDNA-transfected NMH cells underwent cell death in response to 12 h of TGF-b1 treatment (Figure 4a ). Ectopic expression of Smad7 inhibited TGF-b1 cell killing in a dose-dependent fashion, indicating Smad7 can antagonize TGF-b1 signaling in (Yamamura et al., 2000) . As expected, cells transfected with the 2N/3CIkB-a construct displayed enhanced cell death (B50%), while cotransfection with a RelA expression vector significantly rescued cell killing by TGF-b1 (Figure 4a ). Furthermore, coexpression of suboptimal amounts of RelA and Smad7 resulted in synergistic protection from cell death in response to TGF-b1 treatment (Figure 4b ). Thus, ectopic expression of Smad7 can reduce cell death mediated by TGF-b1, while inhibition of NF-kB activity potentiates the apoptotic response to TGF-b1 treatment of NMH cells.
We next assessed the effects of TGF-b1 treatment on Smad7 mRNA expression and promoter activity. As shown by Northern analysis, 30 min of TGF-b1 treatment led to upregulation of Smad7 mRNA levels, which remained elevated for up to 24 h (Figure 5a ). Furthermore, the activity of the murine Smad7 promoter was induced approximately threefold in response to TGF-b1 treatment (pSV2Neo, Figure 5b ), suggesting that Smad7 induction occurs at the transcriptional level.
Since NF-kB has been implicated in induction of Smad7 expression in response to TNF-a or CD40L treatments and the consequent inhibition of TGF-b1- , we sought to determine whether NF-kB regulated Smad7 expression in response to TGF-b1 treatment. Coexpression of the phosphorylation-defective mutant 2N/3CIkB-a failed to block TGF-b1-mediated activation of Smad7 promoter (Figure 5b ), whereas it downregulated the luciferase activity of a kBdriven reporter construct by approximately 10-fold (data not shown). These results were further confirmed in (10)1 embryoblasts where the induction of Smad7 mRNA levels following 1 h of TGF-b1 treatment was similarly seen (Figure 5c ). AdIKK-1 K>M and AdIKK-2 K>M vectors failed to suppress Smad7 mRNA levels. Thus, the early induction of NF-kB does not appear to play a direct role in the observed activation of Smad7 in NMH upon TGF-b1 treatment, indicating that NF-kB does not inhibit TGF-b1-mediated apoptosis through upregulation of Smad7 gene expression.
NF-kB inhibits TGF-b1-induction of AP-1 complex activity
Two recent studies have described negative crosstalk between the IKK and JNK pathways based on the ability of NF-kB to inhibit JNK signaling in response to TNF-a, but not IL-1 (De Smaele et al., 2001; Tang et al., 2001) . Thus, we sought to determine whether activation of NF-kB by TGF-b1 inhibits JNK signaling. First, we confirmed c-Jun phosphorylation by JNK in response to TGF-b1 treatment (Figure 6a ), and found a peak at 2-3 h post-treatment in 10(1) cells. To assess whether inhibition of NF-kB activity would lead to increased cJun phosphorylation, WCEs of 10(1) cells, which had been infected with adwtIKK-2 or adIKK-2 K>M and treated for 3 h with TGF-b1, were subjected to immunoblotting using a phospho-specific anti-c-Jun antibody (Figure 6b ). Cells expressing wtIKK-2 displayed low levels of phosphorylated c-Jun after 3 h of TGF-b1 treatment. In contrast, c-Jun phosphorylation levels were dramatically enhanced in TGF-b1-treated cells expressing IKK-2 K>M (approx. eightfold as judged by densitometry), indicating a role of the IKK complex in inhibition of JNK signaling. As previously reported (De Smaele et al., 2001; Tang et al., 2001) , IKK-2 K>M-expressing cells displayed higher levels of c-Jun phosphorylation in response to 3 h of TNF-a treatment compared to wtIKK-2-expressing cells ( Figure 6b ). Next, we assessed the effects of TGF-b1 treatment on AP-1 binding activity in (10)1 cells (Figure 6c ). AP-1 DNA binding activity was induced after 30 min of TGFb1 treatment and remained elevated for up to 3 h. At the 4 h time point, AP-1 binding levels started to decline and were equal to basal levels by 5 h. Since JNK-mediated phosphorylation of the c-Jun transactivation domain stimulates AP-1 complex activity (Karin, 1996) , we asked whether inhibition of IKK activity would result in sustained AP-1 binding and increased transcriptional activities. After 5 h of TGF-b1 treatment, cells expressing IKK-1 K>M or IKK-2 K>M displayed a greater induction of AP-1 binding (3.3-and 3.7-fold, respectively), compared to GFP-infected cells (twofold) or adwtIKK-1 and adwtIKK-2 infected cells (1.5 and 1.8, respectively) that were similarly treated ( Figure 6d ). As seen previously (Figure 2b ), reduced levels of NF-kB binding were seen in the IKK-1 K>M-or IKK-2 K>M-infected cells following TGF-b1 treatment SfiI-XhoISmad7-pGL3 Figure 5 Inhibition of NF-kB activity does not affect induction of Smad7 expression by TGF-b1. (a) TGF-b1 treatment increases Smad7 mRNA levels. NMH cells, in exponential growth, were exposed to 2 ng/ml TGF-b1 for the indicated times, and mRNA samples were subjected to Northern blot analysis using as probe either human Smad7 cDNA, or b-actin to confirm equal loading (bottom panels). (b) Smad7 promoter is activated by TGF-b1. NMH cells in exponential growth were lipofected with the murine Smad7 promoter SfiI-XhoI-luciferase construct or with backbone pGL3 vector in the presence of pSV2Neo vector or dn 2N/3CIkB-a DNA. Following 5 h of treatment with 5 ng/ml TGF-b1, luciferase activity was measured and expressed as fold induction relative to that of BSA-treated cells. Means and standard deviations are representative of three independent experiments carried out in triplicate. (c) Inhibition of NF-kB activity does not affect TGF-b1-mediated upregulation of Smad7 mRNA levels. (10)1 cells were infected with 10 PFU adenoviral constructs directing expression of dn IKK-1 K>M or IKK-2 K>M for 24 h. Subsequently, cells were treated for 1 h with 5 ng/ml TGF-b1 or BSA carrier solution (B). Northern blot analysis was performed using the human Smad7 and rat b-actin cDNA probes
Role of NF-jB in TGF-b1-induced apoptosis M Arsura et al ( Figure 6d ). Thus, inhibition of NF-kB activity in response to TGF-b1 correlates with sustained AP-1 binding activity. Since AP-1 binding activity does not reflect its transcriptional activity, we sought to determine the effects of TGF-b1 and NF-kB inhibition on AP-1 transcriptional activity. For this purpose, NMH cells were transiently transfected with a luciferase reporter construct driven by four tandem AP-1-binding sites from the collagenase promoter (4XTRE-lux) (Williams et al., 2001) in the absence or in the presence of the dn mutant 2N/3CIkB-a. As shown in Figure 7a , cells that had been transfected with empty vectors displayed twofold to fourfold transcriptional activation of the 4XTRE-lux construct after 6 h of TGF-b1 treatment. Inhibition of NF-kB upon ectopic expression of the inhibitor mutant 2N/3CIkB-a further increased activity of 4XTRE-lux construct (approximately eightfold). Furthermore, ectopic expression of RelA repressed 4XTRE activity in response to TGF-b1. Thus, AP-1 transcriptional activity in response to TGF-b1 is potentiated by concomitant suppression of NF-kB activity.
Smads and AP-1 complex have been shown to interact and synergistically promote TGF-b1-mediated transcription and apoptosis (Zhang et al., 1998; Engel et al., 1999; Brodin et al., 2000) . To determine whether inhibition of NF-kB activity would enhance TGF-b1-dependent transcription through activation of JNK, we measured the effect of ectopic expression of 2N/3CIkB-a on transcription of the TGF-b1-responsive reporter construct p3TP-Lux, which contains the Smad-regulated PAI-1 promoter element and three AP-1 binding sites. As control, a truncated form of FosB, DFosB, which heterodimerizes with Jun proteins but lacks the transcriptional domain (Yamamura et al., 2000) , was similarly analyzed. As shown in Figure 7b , the activity of the 3TP-lux reporter was increased by approximately twofold upon TGF-b1 treatment. As predicted by our previous data, ectopic expression of 2N/3CIkB-a further increased the activation of 3TP-Lux activity by TGF-b1 (Bfourfold). This activity was inhibited by coexpression of DFosB. Furthermore, the potentiation of 3TP-Lux activity by 2N/3CIkB-a was completely abolished by ectopic expression of RelA. Thus, NF-kB inhibition NF-kB inhibits TGF-b1-induced apoptosis through downmodulation of AP-1 complex activity Previously, AP-1 complex activity had been shown to play an essential role during TGF-b1-induced apoptosis (Yamamura et al., 2000; Perlman et al., 2001) . Thus, we sought to determine whether rescue by NF-kB from TGF-b1-induced apoptosis was the result of NF-kBmediated disruption of JNK signaling. For this purpose, NMH cells were transfected with a construct directing expression of FosB or DFosB and 2N/3CIkB-a mutant and the control vector (pCDNA). Viable cells were determined upon 16 h of treatment with 5 ng/ml TGFb1. As shown in Figure 8a , approximately 50% mocktransfected NMH cells underwent cell death in response to TGF-b1 treatment. Ectopic expression of DFosB inhibited TGF-b1-cell killing, while FosB potentiated the death response (68% versus 19% dead cells), in good agreement with previous findings (Yamamura et al., 2000) . Cells transfected with the 2N/3CIkB-a construct displayed enhanced cell death (72%), whereas, ectopic expression of DFosB significantly inhibited killing of 2N/3CIkB-a expressing cells by TGF-b1 (32%). Thus, AP-1 complex activity is required for the potentiation of TGF-b1 cell killing via NF-kB inhibition.
Next, we examined the effect of ectopic expression of the well-characterized NF-kB antiapoptotic target XIAP on TGF-b1-mediated cell death. As shown in Figure 8b , NMH cells transfected with the XIAP expression vector displayed enhanced cell survival following TGF-b1 treatment. Importantly, coexpression of XIAP was able to inhibit completely the potentiation of TGF-b1 cell killing by ectopic expression of 2N/ 3CIkB-a, suggesting that XIAP antiapoptotic function lies downstream of NF-kB.
HCCs induced by hepatic expression of mature TGF-b1 or TGF-a/c-myc display elevated NF-kB levels Previously, it was shown that chronic hepatic expression of TGF-b1 in transgenic mice resulted in hepatic fibrosis and apoptotic cell death of hepatocytes (Sanderson et al., 1995) . In addition, approximately 60% of these animals developed hepatocellular carcinomas (HCCs) by 16 months of age and this process could be accelerated by coexpression of the c-myc oncogene (Factor et al., 1997) . Since we have recently found a correlation between aberrant NF-kB expression and neoplastic development of HCCs in TGF-a/c-myc double transgenic mice (Factor et al., 2001) , we asked whether TGF-b1-induced HCCs would similarly display NF-kB activation. The NF-kB binding levels in multiple TGF-b1-induced HCCs (T) were compared to those in normal surrounding liver (SL). Nuclear extracts from three TGF-b1-induced HCCs displayed elevated NF-kB binding compared to their normal adjacent tissues (Figure 9a ). Supershift EMSA identified the complexes as classical (p50/p65) (band 1) and p50 homodimers (band 2) (data not shown).
To determine the effects of constitutive NF-kB activation on JNK signaling, we compared the levels of JNK-mediated phosphorylation of c-Jun in tumors derived from TGF-b1 transgenic mice to those of a tumor obtained from a c-myc transgenic animal that, as we showed previously (Factor et al., 2001) , does not Role of NF-jB in TGF-b1-induced apoptosis M Arsura et al display constitutive NF-kB activity. As depicted in Figure 9b , higher JNK activity was detected with immunoprecipitated JNK-1 of the c-myc-derived tumor (2A21 T) compared to the TGF-b1-derived tumors (F8bT and BxB8 T), consistent with the inhibition of JNK activity by constitutive NF-kB activity in the 2A21 T tumor. To determine directly whether inhibition of NF-kB activity would enhance TGF-b1-dependent transcription through activation of the JNK/AP-1 signaling pathway, we measured the effect of ectopic expression of 2N/3CIkB-a on transcription from the TRE-lux construct in the 223ma2 cell line established from a TGF-a/c-myc-derived HCC, which we found to express constitutive NF-kB activity (data not shown).
As predicted by our previous results, ectopic expression of 2N/3CIkB-a led to an approximately threefold to fourfold increase of AP-1 transcriptional activity (Figure 9c ). Thus, HCCs of TGF-b1 or TGF-a/c-myc transgenic mice display constitutive NF-kB DNA binding activity that downregulates JNK and AP-1 complex activities, indicating a prosurvival role of NFkB in hepatocarcinogenesis.
Discussion
Here, we have identified a novel pathway of TGF-b1 signaling involving a transient upregulation of NF-kB levels through sequential regulation of TAK1 and IKK kinase activities leading to disruption of AP-1 complex activity, which can protect from TGF-b1-induced apoptosis of liver and mammary epithelial cells. Our findings can be summarized in the following scenario. The early activation of NF-kB is promoted by TAK1 to IKK signaling, which leads to phosphorylation and degradation of IkB-a, and the subsequent release of NFkB ( Figure 10 ). The activation of NF-kB induces IkB-a, which promotes repression of NF-kB, thereby inducing cell death. The importance of this subsequent decline in NF-kB levels is highlighted by the observation that inhibition of NF-kB activity potentiates TGF-b1-induced cell killing through sustained phosphorylation of c-Jun and enhanced AP-1 complex transcriptional activity ( Figure 10) . Furthermore, the induction of Smad7 in response to TGF-b1, which appears to be independent of NF-kB, likely plays a role in shutting down the Smad signaling pathway initiated by TGF-b1 rather than mediating cell death rescue by NF-kB. Lastly, our findings with the HCCs suggest that failure of TGF-b1 to suppress NF-kB activity might constitute an alternative pathway leading to aberrant cell survival and thereby development of TGF-b1-induced cancers. NF-kB regulates epithelial cell death during development, regeneration, and neoplastic transformation (Luque and Gelinas, 1997; Barkett and Gilmore, 1999) . TGF-b1 treatment of B-cell lymphomas and epithelial cells was shown to inhibit NF-kB activity, and this effect was essential for TGF-b1-induced apoptosis and growth arrest (Arsura et al., 1996 (Arsura et al., , 1997 Sovak et al., 1999) . Here, we have characterized the regulation of NF-kB activity by TGF-b1 in epithelial cells and murine embryo fibroblasts. We show that a functional IKK-1 and IKK-2 heterodimer is required to promote the early and transient IkB-a phosphorylation and NF-kB activation in response to TGF-b1 treatment. Recent findings have indicated distinct functions of IKK-1 and IKK-2 during cytokine-induced activation of NF-kB and during development (Li et al., 1999b; Tanaka et al., 1999; Hu et al., 2001; Senftleben et al., 2001) . Although IKK-2 has been shown to be essential for NF-kB activation during immune response, the ability of IKK-1 Role of NF-jB in TGF-b1-induced apoptosis M Arsura et al to complement IKK-2 deficiency remains controversial Li et al., 1999a; Takeda et al., 1999) . Here, we report that both IKK-1 and IKK-2 kinase activities are required for efficient induction of NF-kB by TGF-b1. Thus, our data defines a novel function of IKK-1 as an essential mediator of TGF-b1-induced NF-kB activation. Since IKK-1 null mice display morphogenic defects (Hu et al., 1999; Takeda et al., 1999) , it will be crucial to determine whether other TGF-b family members, which have been implicated in the regulation of vertebrate development (Chang et al., 2001) , signal through IKK-1. In addition, we have identified TAK1 as an upstream mediator of IKK activation. Previously, TAK1 has been implicated in NF-kB activation in response to IL-1, LPS, and TNF-a (Sakurai et al., 1999; Irie et al., 2000; Takaesu et al., 2000; Wang et al., 2001) . However, Sakurai and coworkers did not observe TAK1-mediated IkB-a phosphorylation in TGF-b1-treated HeLa cells, which do not display NF-kB activation in response to TGF-b1 (Sakurai et al., 1999) . Here we show that ectopic expression of a dn TAK1, which previously has been shown to repress TNF-a-and IL-1-induced NF-kB activation , efficiently inhibited IKK-1 and NF-kB activities in response to TGF-b1. This observation is consistent with the essential role of IKK-1 in NF-kB activation by TGFb1, although we cannot exclude that TAK1 might be activating IKK-2 as well. Previously, TAK1 has been shown to induce MKK4, MKK3, and MKK6 activities in response to TGF-b1 and BMP-2 (Moriguchi et al., 1996; Shirakabe et al., 1997; Kimura et al., 2000) , thereby promoting apoptosis through JNK and p38 activation (Kimura et al., 2000; Yamamura et al., 2000) . Thus, it appears that TGF-b family members are able to activate through common mediators both proapoptotic (JNK/AP-1) and antiapoptotic (IKK/NF-kB) pathways, and consequently the balance between these two signaling cascades determines the fate of a cell. In this context, our findings illustrate a novel mechanism regulating such balance based on the ability of NF-kB to disrupt AP-1 complex activity and apoptosis in response to TGF-b1.
Previously, JNK-mediated activation of AP-1 complex has been shown to play a central role during TGFmediated transcriptional regulation and induction of apoptosis (Keeton et al., 1991; Atfi et al., 1997; Perlman et al., 2001) . Furthermore, optimal induction of TGFb1-regulated promoters was shown to involve synergism between JNK and Smad pathways (Yingling et al., 1997;  Figure 9 TGF-b1-and TGF-a/c-myc-induced murine HCCs display enhanced NF-kB DNA-binding activity that inhibits AP-1 complex activity. (a) NF-kB binding activity. Nuclear extracts were isolated from surrounding normal livers (SL) and HCCs (T), and samples subjected to EMSA using as probe either the URE-kB (upper panel) or the Oct-1 oligonucleotide (bottom panel), which confirmed equal loading of samples. Band 1 represents classical NF-kB (p65/p50), band 2 contains p50 homodimers. (b) JNK activity in TGF-b1-induced HCC. WCEs were isolated from two TGF-b1-derived HCCs (F8bT and BxB8 T) and from a c-mycinduced HCC (2A21 T). Following immunoprecipitation (IP) with an antibody against JNK-1, kinase assay was performed as described in legend of Figure 2 . Immunoblotting (IB) was performed with equal aliquots of each JNK-1 immunoprecipitate. The ratio of the OD value of IP to IB is expressed in arbitrary units.
(c) Inhibition of NF-kB activity enhances AP-1 complex transcriptional activity in 223ma2 TGF-a/c-myc HCC cells. 223ma2 cells in exponential growth were plated in triplicate in 96-well plates and transfected by lipofection with 50 ng 4XTRE-lux (NMH) construct in the absence (lane 1) or in the presence of 1, 10, 20, and 50 ng 2N/ 3C-IkB-a expression vector (lanes 2, 3, 4, and 5, respectively) and an internal control renilla luciferase expression plasmid. Total DNA concentration was adjusted to 150 ng with backbone vector DNA. After 24 h of incubation, luciferase activity was measured and expressed as fold induction relative to that of mock transfected cells that was set at 1. Means and standard deviations are representative of three independent experiments carried out in triplicate
Role of NF-jB in TGF-b1-induced apoptosis M Arsura et al Zhang et al., 1998; Engel et al., 1999; Brodin et al., 2000; Yamamura et al., 2000) , whereas NF-kB activity repressed TGF-b1-driven transcription (Nagarajan et al., 2000) . Although NF-kB has been proposed to inhibit TGF-b1 signaling through upregulation of the inhibitory Smad7 gene (Bitzer et al., 2000; Patil et al., 2000) , we have been unable to observe direct Smad7 regulation by NF-kB in response to TGF-b1 or TNF-a. Instead, we found that the transcriptional activity of the PAI-1 promoter, which is synergistically regulated by Smad and AP-1 (Zhang et al., 1998; Engel et al., 1999) , was potentiated by repression of NF-kB activity. Thus, our data are consistent with a model in which the negative crosstalk between IKK and JNK pathways ultimately affects the synergistic cooperation and reciprocal reinforcement between AP-1 and Smads ( Figure 10 ). Recently, two independent studies have shown that IKK negatively regulated JNK-mediated phosphorylation of c-Jun in response to TNF-a through induction of the two NF-kB target genes MyD118/GADD45b (De Smaele et al., 2001) and XIAP (Tang et al., 2001 ) that have been previously implicated in TGF-b1-mediated signaling (Selvakumaran et al., 1994; Yamaguchi et al., 1999; Birkey Reffey et al., 2001) . Our results indicate that ectopic expression of one of these two genes, XIAP, rescues cells from TGF-b1-induced apoptosis when NFkB activation and therefore AP-1 inhibition is blocked by coexpression of a superrepressor form of IkB-a. XIAP has been shown to inhibit apoptosis by neutralizing caspase activity (Holcik and Korneluk, 2001 ). In addition, XIAP has been shown to interact with TAK1/ TAB1 functioning as a positive regulator of BMP signaling pathway . Thus, it will be important to determine whether XIAP exerts its inhibitory action upstream or downstream of JNK activation.
Lastly, the observation that HCCs arising from TGF-b1 or TGF-a/c-myc transgenic mice express constitutive NF-kB activity suggests that the prevention of JNK activation by NF-kB-induced genes might accelerate epithelial neoplastic progression. Studies are underway to determine the inter-relationship between IKK and JNK during liver tumor formation. Model for the negative regulation of AP-1 complex activity and apoptosis by NF-kB. IKK, JNK, and SMAD pathways are activated following TGF-b1 stimulation. AP-1 and SMAD cooperate to induce transcriptional response and apoptosis by TGF-b1, whereas NF-kB promotes survival. The data suggests that these opposite effects are modulated by negative crosstalk between IKK and JNK pathways. The shut-off of NF-kB is promoted by induction of the IkB-a inhibitory protein.
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